Pacmilimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade

Pacmilimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade Pacmilimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade Introduction

Pacmilimab Biosimilar is a monoclonal antibody that targets the immune checkpoint protein CD274, also known as programmed death-ligand 1 (PD-L1) or B7-H1. This biosimilar is a research grade version of the original Pacmilimab, which is a therapeutic antibody used for the treatment of various cancers.

Structure

Pacmilimab Biosimilar is a fully humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to CD274, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity

CD274, or PD-L1, is a protein that is expressed on the surface of various cells, including cancer cells. It interacts with the programmed cell death protein 1 (PD-1) on T cells, leading to inhibition of T cell activation and proliferation. This mechanism is used by cancer cells to evade the immune system and promote tumor growth. Pacmilimab Biosimilar works by binding to CD274 and blocking its interaction with PD-1, thereby restoring T cell activity and enhancing anti-tumor immune responses.

Application

Pacmilimab Biosimilar is primarily used for research purposes, including in vitro and in vivo studies to investigate the role of CD274 in cancer and immune responses. It can also be used for the development and testing of new therapeutic strategies targeting PD-L1. Additionally, Pacmilimab Biosimilar can be used as a reference standard for quality control and comparability studies of the original Pacmilimab or other biosimilars targeting CD274.

Therapeutic Target

CD274, or PD-L1, is a promising therapeutic target in cancer treatment. It is overexpressed in various types of cancer, including lung, breast, and bladder cancer, and has been associated with poor prognosis and resistance to conventional therapies. By targeting CD274, Pacmilimab Biosimilar has the potential to enhance the anti-tumor immune response and improve patient outcomes.

Conclusion

Pacmilimab Biosimilar is a research grade version of the therapeutic antibody targeting CD274, also known as PD-L1 or B7-H1. It is a fully humanized monoclonal antibody with a molecular weight of approximately 150 kDa. By binding to CD274 and blocking its interaction with PD-1, Pacmilimab Biosimilar has the potential to enhance anti-tumor immune responses and improve cancer treatment. It is primarily used for research purposes and can also serve as a reference standard for quality control and comparability studies.